- ¹ Can routine antenatal data be used to
- ² assess HIV antiretroviral therapy
- ³ coverage among pregnant women?
- ⁴ Evaluating the validity of different data
- sources in the Western Cape, South
 Africa
- 7

8 9	Nisha Jacob ¹ , Brian Rice ² , Alexa Heekes ^{1,3} , Leigh F. Johnson ¹ , Samantha Brinkmann ³ , Tendesayi Kufa ^{4,5} , Andrew Boulle ^{1,3}
10	¹ School of Public Health, University of Cape Town, Cape Town, South Africa
11	² University of Sheffield, Sheffield, United Kingdom
12	³ Western Cape Government: Health and Wellness, South Africa
13 14	⁴ Center for HIV and STI, National Institute for Communicable Diseases, Johannesburg, South Africa
15	⁵ School of Public Health, University of Witwatersrand, Johannesburg, South Africa
16	
17	
18	
19	
20	
21	
22	
23	
24	

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

25 Abstract

26 Background

Accurate measurement of antenatal antiretroviral treatment (ART) coverage in pregnancy is imperative in tracking progress towards elimination of vertical HIV transmission. In the Western Cape, South Africa, public-sector individual-level routine data are consolidated from multiple sources, enabling the description of temporal changes in population-wide antenatal antiretroviral coverage. We evaluated the validity of different methods for measuring ART coverage among pregnant women.

33 Methods

We compared self-reported ART data from a 2014 antenatal survey with laboratory assay data 34 35 from a sub-sample within the survey population. Thereafter, we conducted a retrospective cohort analysis of all pregnancies consolidated in the Provincial Health Data Centre (PHDC) 36 from January 2011 to December 2020. Evidence of antenatal and HIV care from electronic 37 platforms were linked using a unique patient identifier. ART coverage estimates were 38 39 triangulated with available antenatal survey estimates, aggregated programmatic data from registers recorded in the District Health Information System (DHIS) and Thembisa modelling 40 estimates. 41

42 Results

Self-reported ART in the 2014 sentinel antenatal survey (n=1434) had high sensitivity (83.5%),
specificity (94.5%) and agreement (k=0.8) with the gold standard of laboratory analysis of
ART. Based on linked routine data, ART coverage by the time of delivery in mothers of live
births increased from 67.4% in 2011 to 94.7% by 2019. This pattern of increasing antenatal
ART coverage was also seen in the DHIS data, and estimated by the Thembisa model, but
was less consistent in the antenatal survey data.

49 Conclusion

50 This study is the first in a high-burden HIV setting to compare sentinel ART surveillance data 51 with consolidated individuated administrative data. Although self-report in survey conditions 52 showed high validity, more recent data sources based on self-report and medical records may 53 be uncertain with increasing ART coverage over time. Linked individuated data may offer a 54 promising option for ART coverage estimation with greater granularity and efficiency.

55

56 Introduction

Accurate measurement of antenatal antiretroviral treatment (ART) coverage in pregnancy is imperative in tracking progress towards the elimination of vertical transmission[1–3]. To monitor progress towards elimination of vertical transmission, the Global Plan for the elimination of mother-to-child transmission requires countries to report on three process measures with the targets that 95% of pregnant women attend antenatal care, 95% are tested for HIV and 95% of HIV positive pregnant women initiate ART prior to or during pregnancy[1].

Antenatal HIV sentinel surveillance is one approach to measuring these process indicators, 63 and is a long-standing tool used in South Africa[4-7]. Since 1990, antenatal HIV sentinel 64 surveys have taken place annually or biennially in all provinces of South Africa. Until 2015, 65 the Western Cape province of South Africa extended the national survey to a larger 66 proportionally weighted sample to generate sub-district level estimates. The World Health 67 Organization (WHO) has recommended sentinel surveillance be replaced by routine 68 programmatic data, a shift that is reliant on accurate and complete routine data[7,8]. While the 69 focus of sentinel antenatal surveys is HIV seroprevalence, the widespread roll-out of ART 70 71 necessitates the monitoring of ART coverage in conjunction with prevalence to accurately measure progress in managing HIV and preventing transmission[9]. 72

In 2013, the Western Cape province of South Africa adopted a policy of lifelong ART for all
 pregnant women living with HIV (WLWH) (Option B+)[10,11]. Subsequently, the Western

75 Cape Provincial Department of Health (WCDOH) added an additional guestion on ART use to the 2014 provincial antenatal survey, which was also incorporated in national surveys [12-14]. 76 This guestion measured current ART use in the 3 days prior to survey participation[12]. The 77 validity of self-reported ART use as a method to evaluate ART coverage using existing sentinel 78 79 surveillance methods requires formal evaluation. An alternative method for measuring ART 80 use is using routine data. The WCDOH makes use of two routine health information platforms. 81 Firstly, aggregated data from facility-based registers are captured in the District Health 82 Information System (DHIS). Secondly, individuated electronic patient data are consolidated 83 by the Provincial Health Data Centre (PHDC). These include administrative, pharmacy and laboratory data linked via a unique patient folder number, in the absence of electronic medical 84 85 records. ART coverage can therefore be estimated using pharmacy dispensing data of tripleregimen ART or entries in HIV treatment registers. 86

We evaluated the validity of different methods for measurement of ART coverage by assessing
self-reported ART use in sentinel antenatal surveys and comparing sentinel survey estimates
with routine programmatic data estimates over a 10-year period.

90 Methods

This study was conducted in the Western Cape province of South Africa. The province is comprised of six districts: Cape Metro, Overberg, Garden Route, Central Karoo, West Coast and Cape Winelands. The study was comprised of two parts: validation of 2014 self-reported ART data with laboratory data, and the comparison of cross-sectional sentinel survey ART coverage estimates as well as modelling estimates with routine data from 2011 to 2020. The datasets used are described below.

97 Antenatal survey data

Antenatal ART coverage estimates for the Western Cape Province for 2014 and 2015 were
obtained from the Western Cape provincial sentinel antenatal survey. In 2016, the provincial
survey was discontinued and annual national surveys were replaced by biennial surveys.

Antenatal ART coverage estimates for the Western Cape province for 2017 and 2019 were obtained from the South African National Department of Health as reported in the national sentinel antenatal survey reports.

104 Estimates were derived from data that included all pregnant women attending their first antenatal visit in a public health facility during a 6-week period of a survey in years 2014 and 105 2015. In years 2017 and 2019, the national survey data included pregnant women attending 106 first antenatal visits or follow-up antenatal visits in a public health facility during a 6-week 107 period (in this current analysis, only data collected at first antenatal visit are included). The 108 109 survey question for current ART use in 2014, 2015 and 2017 surveys was: "Have you taken ARVs in the last 3 days?". This guestion measured ART use at enrolment as a proxy for ART 110 use prior to the pregnancy or by the time of conception, excluding any prior treatment 111 interruption. This question was discontinued in 2019. In 2017 and 2019, participants were 112 113 asked if they had ever taken ARVs and if so when, therefore measuring any ART use (prior or current). From 2019, the health care worker asking the guestion was further expected to verify 114 the response with information in the participant's medical records if available. 115

116 Laboratory validation sub-sample

As part of a WCDOH analysis, a third of the HIV positive specimens from the 2014 provincial antenatal survey were sampled, stratified by district, obtaining a sub-sample of 450 specimens. These were tested by the University of Cape Town (UCT) Department of Pharmacology for lopinavir, efavirenz and nevirapine, using a cut-off of 50ng/ml. At least one of these drugs were included in all ART regimens in use in South Africa in 2014. These data were used to validate the additional survey question on current ART use introduced in the 2014 provincial antenatal survey.

124 Provincial Health Data Centre (Routine individual-level HIV program data)

A retrospective cohort of pregnancies was enumerated from the PHDC on 26 May 2022, which
 included anonymised linked data of all pregnant women attending public health facilities in the

127 Western Cape between 2011 to 2020. Pregnancies were allocated a guantitative confidence 128 score to measure the degree of confidence in the recorded information/data points, indicating 129 a true pregnancy. Pregnancies scoring 0.7 or higher out of a maximum of 1 were included as they have at least 1 high confidence data point such as a rhesus antibody test (conducted 130 131 routinely at first antenatal visit), pregnancy test, International Classification of Diseases (ICD) 132 Tenth Revision code indicating pregnancy, antenatal visit or maternal discharge summary. The geographic location of the facility of first pregnancy-related attendance was used to 133 134 determine district of pregnancy. Pregnancy outcome date and available information on 135 gestational age were used to estimate pregnancy period, with the date of the first evidence of pregnancy used to stratify pregnancies by year. Within this cohort, administrative, laboratory 136 and pharmacy evidence of HIV diagnosis before or during the estimated pregnancy period 137 was used to determine antenatal HIV status. Antenatal ART coverage was based on the 138 139 proportion of women known to be living with HIV during the antenatal period with evidence of ART initiation before or during pregnancy. Women who interrupted treatment would be 140 included as having started ART by enrolment. 141

142 District Health Information System (Routine aggregated HIV program data)

Aggregated program data of women recorded as attending public antenatal facilities in the Western Cape for the first time in 2011 to 2020 were included in the DHIS dataset. For this analysis, the element "Known HIV positive client on ART at first visit" was used to determine ART coverage at first antenatal visit among all those known with HIV before pregnancy and diagnosed with HIV at first antenatal visit. This data element is intended to measure ART use at conception and excludes women who had interrupted treatment at the time of the first antenatal visit.

150 Thembisa Model

151 Thembisa is an integrated demographic and HIV model, developed for South Africa. The 152 model is applied at both national and provincial levels; the estimates used in this study are

153 from version 4.6 of the Western Cape model[15]. The provincial model is calibrated to a number of HIV data sources: age-specific HIV prevalence data from antenatal clinic surveys 154 and household surveys, recorded numbers of deaths by age and sex, total numbers of ART 155 patients and age/sex distributions of ART patients, and antiretroviral metabolite data. 156 157 Assumptions about fertility rates in HIV-positive women and the effect of ART on fertility are informed by Western Cape PHDC data[16]. The model makes assumptions about rates of 158 159 ART interruption and re-initiation, which make it possible to estimate both current ART 160 coverage and proportions of WLWH ever initiated on ART at the time of conception.

161 Analysis

Data were analysed using Stata 17 (Stata Corporation, College Station, Texas, USA). 162 Descriptive characteristics of the laboratory validation sub-sample were tabulated. Given the 163 higher validity of laboratory-based ART testing[17], this dataset functioned as the gold 164 standard for comparison with the newly introduced survey question in 2014[9]. Discordance 165 166 between self-report and laboratory ART was calculated. Demographic risk factors for discordance were analysed using logistic regression. Sensitivity, specificity, positive predictive 167 value and negative predictive value were calculated to validate the survey question on ART 168 use. Agreement between self-report and lab ART detection was quantified using the kappa 169 170 statistic.

Given the 10-year duration of the PHDC cohort (2011 – 2020) and the notable changes in ART guidelines and data availability over this time period, descriptive characteristics of the cohort were tabulated across all years and for the 2019 cohort specifically, as the most recent year pre-COVID19, to reflect the most recent characteristics.

ART-specific survey data and time trends from 2014 to 2019 were compared with PHDC, DHIS and Thembisa 4.6 estimates. The 2014 and 2015 provincial antenatal survey measured current ART use (excluding treatment interruption). The 2017 and 2019 national antenatal surveys measured any ART use before pregnancy (which may include treatment interruption).

ART coverage estimates from the surveys were compared with PHDC estimates for women initiating ART before pregnancy among those with prenatal or antenatal evidence of HIV diagnosis (includes treatment interruption). The survey data were similarly compared with DHIS data which were limited to first visit ART coverage (excluding treatment interruption). The survey estimates, PHDC ART coverage estimates before pregnancy and DHIS estimates were further compared with ART at conception estimates from the Thembisa mathematical model estimates for the Western Cape, with and without treatment interruption [15].

PHDC estimates for women initiating ART before or during pregnancy among those with 186 187 prenatal or antenatal evidence of HIV diagnosis (both with live births or any pregnancy outcome) were further compared with Thembisa estimates of ART at delivery among those 188 with live births. A sensitivity analysis including moderate-low confidence pregnancies was 189 conducted to determine the contribution of these pregnancies to ART coverage. The PHDC 190 191 data were analysed further for estimates of ART coverage by district and age-group. These analyses were limited to a 5-year period (2015 – 2020) when the test and treat ART policy 192 193 was fully implemented and individuated electronic data systems were better established.

194 Ethical considerations

The study was approved by the University of Cape Town Human Research Ethics Committee (HREC 083/2021) and the Western Cape Provincial Health Research Committee. All antenatal HIV survey data, DHIS and Thembisa data were provided in aggregated form. Data from the PHDC were de-identified before study release according to the Western Cape Department of Health Data Access Policy Guidelines.

200 Results

From 1 January 2011 to 31 December 2020, 977 800 and 989 568 pregnancies were recorded by the PHDC and DHIS, respectively, with the PHDC enumerating more pregnancies than DHIS from 2015 onwards. Sample sizes for the provincial surveys in 2014 and 2015 were

- 204 7470 and 7517, respectively. Following the discontinuation of provincial surveys, the Western
- 205 Cape sample size of the national surveys in 2017 and 2019 were 3571 and 3943, respectively.
- 206 The descriptive characteristics of the laboratory sub-sample were comparable to the 2014 HIV
- 207 positive survey population (Table 1). Within the sub-sample, 13 participants (2.9%) did not
- 208 disclose ART status.

Table 1: Characteristics of HIV-positive women in the laboratory validation subsample compared to antenatal survey, **2014**

		Lab sub- sample (N=450)		2014 Antenatal Survey (N=1434)		
Variable		Median, Percentage	95% Confidence interval	Median, Percentage	95% Confidence interval	
	Cape Winelands	12.0 %	9.3- 15.4	11.9 %	10.3 -13.6	
District	Central Karoo	0.5 %	0.1 – 1.8	0.5 %	0.2 – 1.0	
	Cape Metro	61.9 %	57.3 – 66.3	62.1 %	59.5 – 64.5	
	Garden Route	14.0 %	11.1 – 17.6	14.0 %	12.3 – 15.9	
	Overberg	4.5 %	2.9 - 6.8	4.4 %	3.5 – 5.6	
	West Coast	7.1 %	5.1 -9.9	7.2 %	6.0 - 8.6	
Age in years (n	nedian; IQR)	28	IQR 24 - 33	29	IQR 24 -33	
	10-14	0.2 %	0.03 – 1.6	0.1 %	0.01 – 0.5	
	15-19	5.5 %	3.7 – 8.0	4.3 %	3.3 – 5.5	
	20-24	20.7 %	17.2 -24.8	22.8 %	20.7 – 25.1	
Age	25–29	29.8 %	25.7 – 34.3	30.1 %	27.7 – 32.5	
category	30-34	27.6 %	23.6 – 31.9	27.7 %	25.4 – 30.0	
	35-39	13.7 %	10.8 – 17.2	12.7 %	11.1 – 14.6	
	40-44	2.3 %	1.2 – 4.2	2.2 %	1.6 – 3.1	
	45-49	0.2 %	0.03 – 1.6	0.1 %	0.04 – 0.6	
Age of partner IQR)	in years (median;	32	IQR 28 -32	32	IQR 28 - 37	
	1	22.4 %	18.8 – 26.5	19.2 %	17.6 – 21.7	
	2	37.4 %	33.1 – 42.0	35.5 %	33.0 - 37.9	
	3	25.1 %	21.3 – 29.4	28.7 %	26.4 – 31.0	
Gravidity	4	10.3 %	7.8 – 13.5	12.0 %	10.3 – 13.7	
	5	3.6 %	2.2 – 5.8	3.2 %	2.3 – 4.1	
6		0.9 %	0.3 -2.3 1.0 %		0.6 -1.7	
	>6	0.2 %	0.03 – 1.6	0.4 %	0.1 – 0.8	
Population group	Black African	85.7 %	82.1 – 88.6	85.8 %	83.9 – 87.5	
	Coloured*	14.3 %	11.4 – 17.9	13.9 %	12.2 – 15.8	
	None	3.0 %	1.7 – 5.1	2.2 %	1.6 – 3.2	

Level of	Finished	52.5 %	47.8 – 57.2	52.1 %	49.5 – 54.8
education	primary				
	Finished	42.0 %	37.5 – 46.7	43.2 %	40.6 - 45.8
	secondary				
	Finished	2.5 %	1.4 – 5.1	2.5 %	1.8 - 3.4
	tertiary				
	Single	75.8 %	71.6 – 79.6	76.1 %	73.8 – 78.3
Marital	Married	21.9 %	18.3 – 26.0	22.3 %	20.2 – 24.6
status	Widow	1.4 %	0.6 - 3.0	0.7 %	0.3 – 1.2
	Divorced	0.9 %	0.3 -2.4	0.9 %	0.5 – 1.5
Awareness	Yes	91.0 %	88.0 - 93.4	90.3 %	88.6 - 91.7
of HIV	No	9.0 %	6.6 – 12.0	9.7 %	8.3 – 11.4
status					
Self-reported	ART use**	35.0 %	30.7 – 39.6	35.5 %	33.0 - 38.1
ART		37.2 %	32.8 - 41.8		
detected on					
lab analysis					
	Lopinavir	3.3 %	2.0 - 5.5		
	(LPV)				
	Efavirenz	31.2 %	27.1 – 35.6		
	(EFV)				
	Nevirapine	2.7 %	1.5 -4.7		
	(NVP)				
Overall		9.6 %	7.2 -12.8		
discordance					
	Discordan	3.4 %	2.1 – 5.6		
	ce – ART				
	self-				
	reported				
	but not				
	detected				
	Discordan	6.2 %	4.3 - 8.9		
	ce – ART				
	detected				
	but not				
	self-				
	reported				

211

*This term is applied by the national survey for purposes of service delivery redress 212

213 **Sensitivity 83.5% (95% CI 77.0 – 88.9), specificity 94.5% (95% CI 91.1 – 96.9), kappa 0.8 (p<0.001), NPV 90.5% (95% CI 214 86.5 - 93.6), PPV 90.1% (95% CI 84.2 - 94.4)

215 No risk factors for discordance between the laboratory sub-sample and 2014 survey 216 population were noted on bivariable and multivariable analyses. Self-reported ART use (35%) was similar to ART detected on lab analysis (37.2%), with 2.2% absolute difference. Self-217 reported ART was further compared to laboratory markers showing a sensitivity of 83.5% (95% 218 219 CI 77.0 – 88.9) and a specificity of 94.5% (95% CI 91.1 – 96.9), positive predictive value of 90.1% (95% CI 84.2 - 94.4) and negative predictive value of 90.5% (95% CI 86.5 - 93.6). 220

- Agreement between self-report and laboratory markers was also high at 90.4% (kappa statistic
- 222 0.8, p<0.001).
- 223
- 224 Descriptive characteristics of the PHDC cohort are summarised in Table 2. The majority of
- women (69.8%) having no electronic record of HIV status, suggests either HIV negative (most
- commonly given high antenatal HIV testing coverage) or unknown status. Of those with
- electronic records of positive HIV status, 7.7% had no record of ART (Table 2). Of all pregnant
- women with HIV in the 10-year cohort, 72.6% (95% CI 72.4 72.8) had records of ART
- initiation before or during pregnancy and 87.2% (95% CI 86.8 87.6) in 2019.

Table 2: Descriptive and HIV-specific characteristics of PHDC Cohort (2011 – 2020) compared to PHDC Cohort 2019

	PHDC Cohort 2011 – 2020 (n=977800) Percentage	95% CI	PHDC Cohort 2019 [§] (n= 123907) Percentage	95% CI
Prior electronic evidence of pregnancy*				
1	60.3%	60.2 - 60.4	52.4%	52.1 – 52.6
2	27.2%	27.1 – 27.3	29.7%	29.5 – 30.0
3	9.2%	9.2 – 9.3	12.4%	12.2 – 12.6
4	2.5%	2.48 – 2.54	4.0%	3.9 – 4.1
5 or more	0.8%	0.8 – 0.9	1.5%	1.4 – 1.6
Age (median; IQR)	27.4	22.5 – 31.8	27.2	22.8 - 32.3
Age Category				
<15	0.5%	0.4 – 0.5	0.5%	0.4 – 0.5
15 -19	12.0%	12.0 – 12.1	11.1%	10.9 – 11.3
20 - 24	26.6%	26.5 – 26.7	25.7%	25.5 – 26.0
25 - 29	27.4%	27.3 – 27.5	27.3%	27.1 – 27.6
30 - 34	20.1%	20.1 – 20.2	20.8%	20.6 – 21.0
35 - 39	10.4%	10.3 – 10.4	11.5%	11.3 – 11.7
>39	3.0%	2.97 – 3.03	3.1%	3.0 – 3.2
District**				
Cape Winelands	13.4%	13.3 – 13.5	13.1%	12.9 – 13.2
Central Karoo	0.8%	0.7 – 0.8	1.2%	1.1 – 1.3

Cape Metro	70.2%	70.1 – 70.3	65.7%	65.4 - 65.9
Garden Route	8.3%	8.3 - 8.4	9.2%	9.0 - 9.4
	3.0%	2.9 – 3.0	4.3%	9.0 - 9.4 4.2 - 4.4
Overberg West Coast	3.7%	2.9 - 3.0	4.3% 5.5%	4.2 - 4.4
No district recorded	0.6%	0.61 - 0.64		<u> </u>
	0.0%	0.61 - 0.64	1.1%	1.0 - 1.1
Pregnancy Outcomes				
Delivered	83.4%	83.3 - 83.5	81.1%	80.1 – 81.3
Ectopic pregnancy	1.4%	1.4 – 1.5	1.7%	1.7 – 1.8
Termination	5.4%	5.3 – 5.4	7.2%	7.1 – 7.4
Stillbirth	1.5%	1.4 – 1.5	1.3%	1.2 – 1.4
Miscarriage	3.4%	3.4 – 3.5	4.9%	4.8 - 5.0
Mother died prior to delivery	0.02%	0.01 – 0.02	0.02%	0.01 - 0.03
Outcome unknown	4.9%	4.86 - 4.94	3.8%	3.7 – 3.9
Evidence of HIV status				
HIV status unknown†	69.8%	69.8 - 69.9	71.6%	71.6 – 72.1
HIV status unknown	30.2%	30.1 - 30.3	27.9%	27.9 - 28.4
	30.2 /0	30.1 - 30.3	21.970	27.9 - 20.4
HIV evidence timing				
HIV positive before or during				
pregnancy	16.7%	16.7 – 16.8	18.5%	18.3 – 18.7
HIV positive postnatally	4.0%	4.00 - 4.03	1.4%	1.3 – 1.5
HIV negative	9.5%	9.4 – 9.5	8.3%	8.1 – 8.4
HIV unknown	69.8%	69.7 – 69.9	71.8%	71.6 – 72.1
ART (n=202575)			(n=24644)	
HIV Positive but no evidence of			/	
ART	7.7%	7.6 – 7.8	5.9%	5.6 - 6.2
Antenatal ART (before or during	72.6%	72.4 – 72.8	87.2%	86.8 – 87.6
pregnancy) Postnatal ART	19.7%	19.6 - 19.9	6.9%	6.6 - 7.2
	13.170	19.0 - 19.9	0.970	0.0 - 7.2
Antenatal ART (n=163649)‡			(n=22910)	
ART started before pregnancy	54.7%	54.4 - 54.9	69.5%	68.9 – 70.1
ART started during pregnancy	35.2%	35.0 - 35.4 24.3%		23.7 – 24.9
No antenatal ART	10.1%	10.0 – 10.3	6.2%	5.9 - 6.5

233

234 §2019 reflects the most recent characteristics pre COVID-19

235 *Gravidity estimates in the PHDC are not reliable since historic data are incomplete. Prior electronic evidence is used as a 236 proxy to provide a full description of the cohort.

237 **Unweighted

238 †HIV diagnosis is based on point-of-care tests that are not recorded electronically. Unknown HIV status therefore includes 239 those who tested negative on point-of-care tests and therefore have no subsequent electronic evidence of HIV

240 ‡Excludes women who only tested HIV positive postnatally

241

242 Among those living with HIV, survey, DHIS, PHDC and Thembisa estimates show that ART coverage before pregnancy increased over time, however a slight decrease is noted in the 243 survey estimate in 2019 (Table 3 and Figure 1). The 2014 laboratory and PHDC estimates of 244 ART coverage were almost the same (37.2% v 37.4%, respectively). The 2015 survey 245 estimate of 44.2% was similar to the PHDC estimate of 42.8%. The 2017 survey estimate of 246 62.3% was higher than PHDC data (58.4%), but lower in 2019 (61.2%) compared to PHDC 247 (69.5%), when comparing ART coverage before pregnancy. DHIS estimates were notably 248 higher than Thembisa estimates, excluding treatment interruption, and more aligned to PHDC 249 estimates which included treatment interruption. Thembisa estimates of those ever on ART 250 prior to conception (including treatment interruption), were higher than PHDC until 2016 and 251 thereafter reasonably close to PHDC estimates. From 2015 to 2020, Thembisa estimates of 252 ART at delivery were higher than PHDC estimates of ART at delivery, however the difference 253 254 between estimates is lower when restricting PHDC estimates to live births only. A sensitivity 255 analysis to assess the contribution of moderate-low confidence pregnancies to ART coverage did not materially impact the PHDC estimates and associated comparisons. 256

	Before pregnancy							At delivery	
	Antenatal Survey		DHIS	Thembisa 4.6	PHDC	Thembisa 4.6	PHDC	PHDC	Thembisa 4.6
Year	Antenatal Survey (on ART among WLWH)	Lab validation	Proportion on ART among those with HIV at antenatal first visit (excluding treatment interruption)	Antenatal ART coverage prior to conception (excluding treatment interruption)	Proportion on ART before pregnancy among those known with HIV (includin g treatment interruption)	Antenatal ART coverage prior to conception (including treatment interruption)	Antenatal ART coverage at delivery (all pregnancy outcomes)	Antenata I ART coverag e at delivery (live births only)	Antenatal ART coverage at delivery (live births only)
2011				32.4	27.0	34.8	67.1	67.4	51.7
2012				36.0	33.7	39.2	72.8	73.9	62.3
2013				39.7	35.4	43.5	83.7	85.3	77.0
2014	35.5 (33.0 - 38.0)*	37.2 (32.7 - 41.7)*		43.4	37.4	47.6	88.9	90.6	88.6
2015	44.2 (41.6 - 46.8)*		43.9	47.3	42.8	52.0	90.6	92.4	93.8
2016			51.4	51.0	51.6	56.5	91.4	92.9	95.3
2017	61.5 (57.7 - 65.1)* 62.3 (58.5 - 66.0)**		62.0	54.1	58.4	60.5	92.4	93.9	96.1
2018			62.9	57.1	63.6	64.1	92.6	94.0	96.4
2019	61.2 (57.2 - 65.1)**		68.3	59.7	69.5	67.3	93.8	94.7	96.6
2020			70.1	61.3	72.6	69.5	93.5	94.1	96.7

Table 3: Western Cape Antenatal ART Coverage (%) amongst women living with HIV by dataset (2011 – 2020)

258

259 *Current ART use (excludes treatment interruption)

260 ** Includes treatment interruption. Stratified to first visit only. ART before pregnancy amongst first and follow-up attendees is 58.4 for 2017 and 58.2 for 2019.

Figure 1: ART coverage before and during pregnancy by dataset (2011 – 2020)

Figure 2 presents Western Cape antenatal ART coverage among those with HIV over a 10-262 year period according to PHDC data. ART coverage prior to pregnancy amongst women living 263 264 with HIV increased over time from 42.8% (95% CI 42.0 - 43.5) in 2015 to 72.6% (95% CI 72.0 - 73.1) in 2020. Higher coverage was observed in older age groups, with coverage as high as 265 81.1% in the 35-39 age group in 2020 (Figure 1). An increasing proportion of women are 266 shown to be on ART before pregnancy and from 2015 onwards ART coverage exceeds 90% 267 before or during pregnancy. ART coverage during the antenatal period (ART commenced 268 269 before or during pregnancy) was high amongst pregnant WLWH in all districts, except Central Karoo, and across all years. Over time, there was variability of coverage estimates in Central 270 271 Karoo, Overberg and West Coast, with Cape Metro having the most consistent increase in 272 coverage.

Figure 2: Temporal trends in antenatal ART coverage in the Western Cape by timing, district and age (PHDC)

275 Discussion

Our study is the first to assess and compare different methods of antenatal ART coverage ascertainment in the Western Cape province. All datasets documented the increasing ART coverage in pregnant women over time. The challenges in dataset comparisons where numerators and denominators are disparate were highlighted.

280 The self-reported survey-based antenatal ART question was confirmed as a valid measure of ART use by comparison to the gold standard of laboratory detection, with good overall 281 concordance. Discordance was higher amongst those self-reporting no ART use but having 282 positive laboratory detection of ART than vice versa. This may represent misunderstanding of 283 the question, false positive laboratory results or reluctance in disclosing ART use due to stigma 284 285 or other reasons. Interestingly, 15 participants who self-reported ART use had no laboratory evidence of ART. In addition to guestion misinterpretation or false negative laboratory results. 286 287 this may also suggest poor recent medication adherence. Discordance proportions and

288 agreement between self-report and laboratory detection were in keeping with a similar study conducted in the Kwazulu-Natal province, however non-disclosure of ART status (2.9%) was 289 290 notably lower in our cohort compared to this study[9]. Several other studies in sub-Saharan Africa comparing self-report and biomarkers of current or previous ART use showed higher 291 292 proportions of ART non-disclosure, however these studies had smaller sample sizes and the 293 study population was not restricted to pregnant women presenting for antenatal care[18-21]. 294 While the study by Huerga et. al. in Kwazulu Natal found younger individuals were at higher 295 risk of discordance, our study found no demographic risk factors for discordance[9]. The ART 296 question had high agreement beyond chance, and high specificity, sensitivity and positive and 297 negative predictive values, suggesting good performance of this question as a measure of 298 ART use. Other studies have shown a similarly high specificity and positive predictive value, 299 however sensitivity and negative predictive value are notably lower[22–24]. Reasons for better 300 performance of self-reported ART in our study may include lower social desirability bias due to lower perceived stigma of ART use amongst those actively seeking antenatal care in a 301 302 clinical setting. Furthermore, since the ART question was asked by clinicians during routine 303 clinical care, more explanation of the question may have been given compared to other study 304 settings. Our findings arguably support the continued use of the question in survey settings and the utility of survey ART estimates for further validation with routine data. However, we 305 note that the question on current ART use was discontinued after 2017 and replaced with a 306 question "has the participant ever taken ARV's," thereby including those not on ART at the 307 time due to prior treatment interruption. Additionally, from 2019, survey questions were 308 complemented with information from medical records if available. Further validation of survey 309 data is therefore recommended. 310

From 2015 onwards, the PHDC enumerated more pregnancies than DHIS, suggesting good completeness of these data. Higher numbers in the PHDC may be due to inclusion of nonviable pregnancies and terminations of pregnancy, which may not be captured in DHIS amongst antenatal service attendees. Lower enumeration prior to 2015 is likely due to less

315 well-established electronic systems in earlier years. Within the PHDC cohort, 69.8% had no information of HIV status. This is likely representative of the HIV negative antenatal population 316 317 whose HIV status is determined solely by point-of-care rapid HIV testing, the results of which are not captured electronically on routine information systems [25]. Those with evidence of 318 319 HIV negative status had laboratory confirmation via HIV ELISA test results which are captured 320 electronically on routine systems. Those testing positive for HIV on point-of-care testing may 321 have further validation of test results by laboratory HIV ELISA testing as well as other 322 laboratory, pharmacy and administrative evidences of HIV, thus providing a complete dataset 323 of HIV positive antenatal patients in the public sector of the Western Cape province [25].

Estimates of ART coverage in the HIV positive antenatal population were similar across the 324 survey and PHDC datasets for 2014 and 2015, although higher estimates were expected in 325 2015 due to inclusion of treatment interruption in the PHDC dataset. The 2017 and 2019 326 327 antenatal surveys report ART use prior to pregnancy among women presenting for their first antenatal visit, and therefore may include those who interrupted treatment [13,14]. When 328 compared to PHDC estimates of ART before pregnancy, PHDC estimates were lower than 329 330 survey estimates in 2017, but notably higher in 2019. The differences between survey 331 estimates and PHDC may reflect sampling bias in the survey population as well as interviewerrelated differences in asking the survey question on ART use prior to pregnancy, participant-332 333 related interpretation of the question as well as availability of relevant medical records in 2019 334 survey participants. Whether the estimates include or exclude treatment interruption may be dependent on how the survey question was interpreted by both interviewer and participant. 335

Thembisa estimates of ART at delivery were higher than PHDC estimates, however the difference was slightly less when restricting PHDC estimates to live births only. This may indicate that ART initiation is prioritised where transmission to an infant is possible, and less urgent in non-viable pregnancies such as ectopic pregnancies. Additionally, pregnancies where the outcome is unknown may represent those who are lost to the health care system for reasons such as migration to a different province and therefore not recorded on ART within

the PHDC. The high ART coverage estimates reflected in the PHDC dataset is reassuring and in keeping with recent literature[26]. These findings support the importance of antenatal first visits for early engagement in HIV care and effective prevention of vertical transmission of HIV. Any antenatal engagement with health services for WLWH, regardless of pregnancy intention or outcome, should be considered an opportunity for ART initiation in keeping with test and treat guidelines. Systemic factors associated with delayed ART initiation requires urgent research in order to optimise prevention of vertical transmission of HIV.

349 DHIS estimates of ART coverage among WLWH at first antenatal visit are notably higher than 350 survey estimates and Thembisa estimates and more aligned to PHDC estimates, despite differences in treatment interruption ascertainment. The reasons for these disparities may be 351 multifactorial and difficult to identify. It should be noted that Thembisa estimates include both 352 the private and public sector. When including treatment interruption, Thembisa estimates are 353 354 notably higher than PHDC estimates until 2016. PHDC estimates may be higher in recent 355 years and increasing over time due to greater ascertainment of patients using the public sector 356 for HIV services. Overall, PHDC estimates appear to track Thembisa estimates closely in 357 recent years, supporting the use of these routine individuated data for surveillance purposes 358 in this setting. DHIS estimates include those currently on ART (excluding those interrupting 359 ART) and trends may further represent changes in capturing of routine information on service-360 based registers or other contextual factors. While DHIS indicators are clearly defined, the 361 exact question asked to ascertain current ART use at first antenatal visit may differ from clinician to clinician, resulting in variable patient interpretation and responses. Where data is 362 not collected for research purposes it is difficult to determine how a question is asked. Data 363 sources based on responses therefore may be uncertain, particularly with increasing ART 364 coverage over time. 365

Population-wide datasets from the PHDC allow better discernment of current ART versus ever on ART and more detailed analysis such as district-level and age disaggregated temporal trends, which the antenatal survey is underpowered to generate, while the DHIS is limited to

369 specific indicators. Age-group trends over time show an expected higher ART coverage prior 370 to pregnancy in older age groups who have likely had more opportunities for HIV diagnosis 371 and care than younger age groups (in whom HIV is likely to have been more recently acquired). District-level trends are in keeping with provincial trends, showing a high ART 372 373 coverage during the antenatal period, with most districts above 90%. The lower and less 374 precise coverage estimates in Central Karoo are reflective of the smaller population and lower HIV prevalence in this sparsely populated rural district. Other demographic characteristics 375 376 associated with ART coverage could not be evaluated as these are not routinely captured in 377 health information systems.

378 Limitations

379 Routine data are subject to various caveats impacting both quality and completeness. Given 380 the wide range of information systems used and the diverse staff members involved in data capturing, these data are subject to varying administrative and capturing errors. Completeness 381 382 of data cannot be accurately quantified as demonstrated in the limited PHDC data available prior to 2015. Contextual factors at different facilities may further impact the quality of data -383 this includes changes in capturing approaches, staff training, staff turnover, and COVID-19 384 pandemic impacts. Ascertainment of both pregnancy and ART use is dependent on how 385 386 electronic systems are used in different facilities. However, the PHDC approach to using multiple data sources to enumerate pregnancy and HIV ascertainment, may mitigate against 387 gaps in single data sources such as DHIS. ART coverage ascertained from routine data is 388 inferred through dispensing of ART from pharmacy. This does not necessarily translate to 389 390 administration and adherence to ART.

This study highlights the challenges in comparing datasets with differing numerators and denominators, particularly with respect to treatment interruption. Routine data are limited to variables captured routinely. Since information specific to the first antenatal visit is not routinely captured in all public health facilities, it was not possible to distinguish between first and followup antenatal visits in the PHDC dataset. While first visit can be ascertained in DHIS,

aggregated data are susceptible to double counting if the patient attends multiple antenatalclinics.

Detailed demographic and treatment characteristics are not captured, precluding a deeper understanding of epidemiological trends. DHIS consists of data elements for both national and provincial reporting purposes, some of which measure the same variable but are captured in different registers and by different staff members. As such, different data elements may be used for both numerator and denominator in order to calculate ART coverage. ART estimates may therefore vary depending on the data elements selected.

Since the national antenatal survey is underpowered for detailed estimates, routine data cannot be adequately validated at district, sub-district and age-group levels. Furthermore, the findings on self-reported ART use in surveys reflect findings in the last decade. We recommend repeating the validation to confirm if this concordance has persisted.

Lastly, it should be noted that while Thembisa estimates were used for comparison with antenatal survey and PHDC estimates, the Thembisa model is partially dependent on estimates from the antenatal survey for model calibration and assumptions on fertility are derived from the PHDC.

412 Conclusion

Our study demonstrates the validity and utility of antenatal ART coverage using routine 413 individuated data. While laboratory detection is the most accurate measure of ART use, this 414 is neither affordable nor practical at a population level. Routine individuated data provide an 415 efficient and less costly method of estimation compared to surveys and more accuracy and 416 granularity than aggregate data. Trends in the Western Cape province are reassuring in that 417 418 the large majority of HIV positive women are initiated on ART before or during pregnancy. This 419 is supportive of the province soon meeting the third target of the Global Plan for elimination of mother-to-child transmission of 95% of HIV positive women initiating ART prior to or during 420 421 pregnancy. Reasons for non-initiation during pregnancy require further investigation as this has serious implications for prevention of vertical transmission and child morbidity and mortality. Strengthening of routine information systems, including improved digitisation of point-of-care HIV testing and ascertainment of treatment interruption, in addition to being invaluable tools to directly support patient care, may allow more accurate epidemiological trend analysis for timely action and improved quality of HIV care.

427 Acknowledgements

The authors gratefully acknowledge the contributions of various collaborators, including Selamawit Woldesenbet, Emma Kalk, Florence Phelenyane, Adrian Puren, Kathryn Stinson, University of Cape Town Department of Pharmacology, the Western Cape Department of Health, the National Institute of Communicable Diseases, the South African National Department of Health and the Measurement and Surveillance of HIV Epidemics (MeSH) consortium.

434 Funding

435 We gratefully acknowledge funding from the Bill and Melinda Gates Foundation 436 (OPP1191327).

437 **References**

- World Health Organization. Global guidelines on criteria and processes for validation:
 elimination of mother-to-child transmission of HIV and Syphilis monitoring. Int J
 Gynecol Obstet. 2014;143:155–6.
- 441 2. UNAIDS/World Health Organisation Working Group on Global HIV/AIDS and STI
- 442 surveillance. Guidelines for assessing the utility of data from prevention of mother-to-
- 443 child transmission (PMTCT) programmes for HIV sentinel surveillance among
- 444 pregnant women. 2013; Available from:
- 445 https://www.ncbi.nlm.nih.gov/books/NBK159001/pdf/Bookshelf_NBK159001.pdf

446 (Accessed 30 January 2023)

- Wessels J, Sherman G, Bamford L, Makua M, Ntloana M, Nuttall J, et al. The updated
 South African National Guideline for the Prevention of Mother to Child Transmission
 of Communicable Infections (2019). South Afr J HIV Med. 2020;21(1):1–8.
- 450 4. Mirkuzie AH, Sisay MM, Hinderaker SG, Moland KM, Mørkve O. Comparing HIV
- 451 prevalence estimates from prevention of mother-to-child HIV transmission programme
- 452 and the antenatal HIV surveillance in Addis Ababa. BMC Public Health. 2012;12(1).
- 453 5. Gouws E, Mishra V, Fowler TB. Comparison of adult HIV prevalence from national
- 454 population-based surveys and antenatal clinic surveillance in countries with
- 455 generalised epidemics: implications for calibrating surveillance data. Sex Transm
 456 Infect. 2008;84(Suppl I):i17-23.
- 6. Rehle T, Lazzari S, Dallabetta G, Asamoah-odei E, Rehle T. Second-generation HIV
- 458 surveillance: better data for decision-making. Bull World Heal Organ. 2004;82:121–7.
- Dee J, Calleja JMG, Marsh K, Zaidi I, Dee J. HIV Surveillance Among Pregnant
 Women Attending Antenatal Clinics : Evolution and Current Direction. JMIR Public
 Heal Surveill. 2017;3:1–8.
- World Health Organization. Consolidated guidelines on HIV testing services [Internet].
 2015. Available from: https://www.who.int/hiv/pub/guidelines/hiv-testing-services/en/
 (Accessed 30 January 2023)
- Huerga H, Shiferie F, Grebe E, Giuliani R, Farhat J Ben, Van-Cutsem G, et al. A
 comparison of self-report and antiretroviral detection to inform estimates of
 antiretroviral therapy coverage, viral load suppression and HIV incidence in KwazuluNatal, South Africa. BMC Infect Dis. 2017;17(1):1–8.
- 469 10. Osler M, Hilderbrand K, Hennessey C, Arendse J, Goemaere E, Ford N, et al. A
 470 three-tier framework for monitoring antiretroviral therapy in high HIV burden settings. J

471 Int AIDS Soc. 2014;17:18908.

- 11. Mofenson LM. Antiretroviral Therapy and Adverse Pregnancy Outcome: The Elephant
- in the Room? J Infect Dis [Internet]. 2015;jiv390. Available from:
- 474 http://jid.oxfordjournals.org/lookup/doi/10.1093/infdis/jiv390
- 475 12. Jacob N. Western Cape Antenatal Survey Report 2014. Cape Town; 2014.
- 13. Woldesenbet S, Kufa T, Lombard C, Manda S, K A, M C, et al. The 2017 National
- 477 Antenatal Sentinel HIV Survey, South Africa, National Department of Health.
- 478 [Internet]. 2019. Available from: https://www.nicd.ac.za/wp-
- 479 content/uploads/2019/07/Antenatal_survey-report_24July19.pdf (Accessed 30
- 480 January 2023)
- 481 14. Woldesenbet S, Lombard C, Manda S, Kufa T, Ayalew K, Cheyip M, et al. The 2019
- 482 National Antenatal Sentinel HIV Survey, South Africa [Internet]. 2021. Available from:
- 483 https://www.nicd.ac.za/wp-content/uploads/2021/11/Antenatal-survey-2019-

484 report_FINAL_27April21.pdf (Accessed 30 January 2023)

- 15. Johnson LF, Dorrington RE. Modelling the impact of HIV in South Africa's provinces:
- 486 2023 update. Thembisa Version 4.6 [Internet]. 2023. Available from:

487 https://www.thembisa.org/downloads (Accessed 30 July 2023)

488 16. Johnson LF, Mutemaringa T, Heekes A, Boulle A. Effect of HIV Infection and

Antiretroviral Treatment on Pregnancy Rates in the Western Cape Province of South
 Africa. J Infect Dis. 2020;(July 2019):21–4.

- 491 17. Xia Y, Milwid RM, Godin A, Boily MC, Johnson LF, Marsh K, et al. Accuracy of self-
- 492 reported HIV-testing history and awareness of HIV-positive status in four sub-Saharan
 493 African countries. Aids. 2021;35(3):503–10.
- 18. Mavhandu-Ramarumo LG, Tambe LAM, Matume ND, Katerere D, Bessong PO.
- 495 Undisclosed exposure to antiretrovirals prior to treatment initiation: An exploratory

496 analysis. South Afr J HIV Med. 2021;22(1):1–10.

- 497 19. Sithole N, Gunda R, Koole O, Krows M, Schaafsma T, Moshabela M, et al.
- 498 Undisclosed Antiretroviral Therapy Use at Primary Health Care Clinics in Rural
- 499 KwaZulu Natal South Africa: A DO-ART Trial Sub-study. AIDS Behav [Internet].
- 500 2021;25(11):3695–703. Available from: https://doi.org/10.1007/s10461-021-03319-4
- 501 20. Kharsany ABM, Cawood C, Lewis L, Yende-Zuma N, Khanyile D, Puren A, et al.
- 502 Trends in HIV Prevention, Treatment, and Incidence in a Hyperendemic Area of
- 503 KwaZulu-Natal, South Africa. JAMA Netw Open. 2019;2(11):1–16.
- 504 21. Grobler A, Cawood C, Khanyile D, Puren A, Kharsany ABM. Progress of UNAIDS 90-
- 505 90-90 targets in a district in KwaZulu-Natal, South Africa, with high HIV burden, in the
- 506 HIPSS study: a household-based complex multilevel community survey. Lancet HIV.

507 2017;4(11):e505–13.

508 22. Jennifer TM-G, Julia R, Livia M, Mark S, Guy H, F.Xavier G-O, et al. ART denial:

results of a home-based study to validate self-reported antiretroviral use in rural South
Africa. AIDS Behav. 2019;23:2072–8.

511 23. Grabowski MK, Reynolds SJ, Kagaayi RH, Clarke W, Chang LC, Nakigozi G et. al.

512 The validity of self-reported antiretroviral use in persons living with HIV: a population-513 based study. AIDS. 2018;32(3):363–9.

514 24. Kim A, Mukui I, Young P, Mirjahangir J, Mwanyumba S, Wamicwe J et. al.

515 Undisclosed HIV infection and ART use in the Kenya AIDS Indicator Survey 2012:

516 relevance to targets for HIV diagnosis and treatment in Kenya. AIDS.


517 2016;30(17):2685–95.

Jacob N, Rice B, Kalk E, Heekes A, Morgan J, Hargreaves J, et al. Utility of digitising
point of care HIV test results to accurately measure , and improve performance
towards , the UNAIDS 90-90-90 targets. PLoS One [Internet]. 2020;1–13. Available


521 from: http://dx.doi.org/10.1371/journal.pone.0235471

- 522 26. Astawesegn FH, Stulz V, Conroy E, Mannan H. Trends and effects of antiretroviral
- 523 therapy coverage during pregnancy on mother to child transmission of HIV in Sub -
- 524 Saharan Africa . Evidence from panel data analysis. BMC Infect Dis [Internet].
- 525 2022;1–13. Available from: https://doi.org/10.1186/s12879-022-07119-6

526




Figure



ART coverage before pregnancy by age-group (2015 - 2020)

ART coverage before or during pregnancy by district (2015 - 2020)



Figure